Singapore Indian Eye Study-2: methodology and impact of migration on systemic and eye outcomes.


Journal Article

Asian Indians are the fastest growing migration groups in the world. Studies evaluating the impact of migration on disease outcomes in this population are rare.We describe the methodology of the Singapore Indian Eye Study-2 (SINDI-2) aimed to evaluate the impact of migration status on diabetic retinopathy and other major age-related eye diseases in Asian Indians living in an urban environment.Population-based cohort study.A total of 2200 adults had participated in baseline SINDI (2007-2009, mean age [range] = 57.8 [42.7-84.1] years) and SINDI-2 (2013-2015, 56.5 [48.4-90.2] years).Participants were classified as 'first generation' if they were Indian residents born outside of Singapore and as 'second-generation' immigrants (59.7% in SINDI vs. 63.6% in SINDI-2) if they were born in Singapore.Response rate, participant characteristics and prevalence of systemic diseases were stratified by migration status.Of the 2914 eligible SINDI participants invited to participate, 2200 participated in SINDI-2 (response rate of 75.2%). In both SINDI and SINDI-2, compared with first-generation immigrants, second-generation immigrants were younger, less likely to have income <1000 SGD, had lower levels of pulse pressure, higher levels of high-density lipoprotein cholesterol, had lower prevalence of hypertension and chronic kidney disease and had higher prevalence of current smoking and obesity (all P < 0.05).In both SINDI and SINDI-2, second-generation immigrants had lower prevalence of cardiovascular risk factors except smoking and obesity compared with first-generation immigrants. The final report will confirm if these differences between generations are evident with regard to eye diseases.

Full Text

Duke Authors

Cited Authors

  • Sabanayagam, C; Yip, W; Gupta, P; Mohd Abdul, RB; Lamoureux, E; Kumari, N; Cheung, GC; Cheung, CY; Wang, JJ; Cheng, C-Y; Wong, TY

Published Date

  • November 2017

Published In

Volume / Issue

  • 45 / 8

Start / End Page

  • 779 - 789

PubMed ID

  • 28472538

Pubmed Central ID

  • 28472538

Electronic International Standard Serial Number (EISSN)

  • 1442-9071

International Standard Serial Number (ISSN)

  • 1442-6404

Digital Object Identifier (DOI)

  • 10.1111/ceo.12974


  • eng